Skip to Content
Merck
All Photos(3)

Key Documents

SAB4600084

Sigma-Aldrich

Anti-Rabbit IgG (H+L), CF 568 antibody produced in goat

~2 mg/mL, affinity isolated antibody

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
NACRES:
NA.46

biological source

goat

Quality Level

conjugate

CF 568 conjugate

antibody form

affinity isolated antibody

antibody product type

secondary antibodies

clone

polyclonal

form

buffered aqueous solution

species reactivity

rabbit

concentration

~2 mg/mL

technique(s)

flow cytometry: 1-10 μg/mL
immunocytochemistry: suitable
immunohistochemistry: suitable
indirect immunofluorescence: 1-10 μg/mL

fluorescence

λex 562 nm; λem 583 nm

shipped in

dry ice

storage temp.

−20°C

target post-translational modification

unmodified

General description

Immunoglobulin G (IgG) is a key member of immunoglobulin family. It consists of gamma (γ) heavy chain in the constant (C) region. IgG is a widely expressed serum antibody. Monomeric structure of IgG constitutes two identical heavy chains and two identical light chains with molecular weight of 50kDa and 25kDa respectively. The primary structure of this antibody also contains disulfide bonds involved in linking the two heavy chains, linking the heavy and light chains and resides inside the chains. IgG is further subdivided into four classes namely, IgG1, IgG2, IgG3, and IgG4 with different heavy chains, named γ1,γ2, γ3, and γ4, respectively. IgG is produced and released from CD5+B cells, the predominant lymphocytes in the neonatal cell repertoire. Maternal IgG has an unique ability to transport across the placenta to the fetus. Maternal IgG passively immunizes the infants.

Specificity

Binds all rabbit IgGs

Immunogen

rabbit IgG (H+L)

Application

Anti-Rabbit IgG (H+L), CF 568 antibody produced in goat has been used in immunofluorescence Imaging.

Features and Benefits

Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.

Physical form

Supplied in phosphate buffered saline with 0.05% sodium azide, 50% glycerol and 2 mg/mL bovine serum albumin.

Preparation Note

Protect from light.

Legal Information

This product is distributed by Sigma-Aldrich Co. under the authorization of Biotium, Inc. This product is covered by one or more US patents and corresponding patent claims outside the US patents or pending applications owned or licensed by Biotium, Inc. including without limitation: 12/334,387; 12/607,915; 12/699,778; 12/850,578; 61/454,484. In consideration of the purchase price paid by the buyer, the buyer is hereby granted a limited, non-exclusive, non-transferable license to use only the purchased amount of the product solely for the buyer′s own internal research in a manner consistent with the accompanying product literature. Except as expressly granted herein, the sale of this product does not grant to or convey upon the buyer any license, expressly, by implication or estoppel, under any patent right or other intellectual property right of Biotium, Inc. Buyer shall not resell or transfer this product to any third party, or use the product for any commercial purposes, including without limitation, any diagnostic, therapeutic or prophylactic uses. This product is for research use only. Any other uses, including diagnostic uses, require a separate license from Biotium, Inc. For information on purchasing a license to use this product for purposes other than research, contact Biotium, Inc., 3159 Corporate Place, Hayward, CA 94545, Tel: (510) 265-1027. Fax: (510) 265-1352. Email: btinfo@biotium.com.
CF is a trademark of Biotium, Inc.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

10 - Combustible liquids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Maria Fazzari et al.
Biochimica et biophysica acta. Molecular and cell biology of lipids, 1868(9), 159350-159350 (2023-06-18)
Fibrillary aggregated α-synuclein represents the neurologic hallmark of Parkinson's disease and is considered to play a causative role in the disease. Although the causes leading to α-synuclein aggregation are not clear, the GM1 ganglioside interaction is recognized to prevent this
Line Séguy et al.
Pharmaceutics, 13(10) (2021-10-24)
The activation of 5-HT4 receptors with agonists has emerged as a valuable therapeutic strategy to treat Alzheimer's disease (AD) by enhancing the nonamyloidogenic pathway. Here, the potential therapeutic effects of tegaserod, an effective agent for irritable bowel syndrome, were assessed
Yamei Zhang et al.
Viruses, 14(4) (2022-04-24)
Coronaviruses (CoVs) have caused several global outbreaks with relatively high mortality rates, including Middle East Respiratory Syndrome coronavirus (MERS)-CoV, which emerged in 2012, and Severe Acute Respiratory Syndrome (SARS)-CoV-1, which appeared in 2002. The recent emergence of SARS-CoV-2 highlights the
Christophe Rochais et al.
British journal of pharmacology, 177(9), 1988-2005 (2019-12-28)
We recently identified donecopride as a pleiotropic compound able to inhibit AChE and to activate 5-HT4 receptors. Here, we have assessed the potential therapeutic effects of donecopride in treating Alzheimer's disease (AD). We used two in vivo animal models of
Claudia Efstathiou et al.
Frontiers in immunology, 15, 1395809-1395809 (2024-06-28)
Human respiratory viruses are the most prevalent cause of disease in humans, with the highly infectious RSV being the leading cause of infant bronchiolitis and viral pneumonia. Responses to type I IFNs are the primary defense against viral infection. However

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service